Artiva Biotherapeutics announced on Tuesday that it is winding down its operations following two patient deaths in a clinical trial testing its cell therapy for autoimmune diseases. The closure marks the latest safety challenge to emerge within the rapidly developing field of cell-based research.
The San Diego-based biotechnology company was evaluating an experimental natural killer cell therapy when the fatalities occurred among trial participants. In the first instance, a participant in the Phase 2 study died from a neurological complication after receiving the treatment. Researchers investigating the fatality determined it was likely not caused by the cell therapy itself, but rather by a chemotherapy regimen administered prior to the infusion. Medical protocols commonly require patients to undergo chemotherapy before receiving cell therapies to reduce white blood cell counts and prepare the body to accept the new cells.
A second participant in the study experienced sudden death approximately two months post-treatment. Company researchers concluded that this fatality was likewise unrelated to any component of the treatment process. However, the precise cause of that participant’s death has not yet been determined.
The winding down of Artiva Biotherapeutics highlights ongoing scrutiny surrounding complex cellular and immunotherapeutic treatments, particularly as researchers explore their applications in treating severe autoimmune conditions. The field has faced a series of safety events across various experimental pipelines, adding regulatory and clinical pressures to companies developing advanced therapies.
